Zacks Research Upgrades Terumo (OTCMKTS:TRUMY) to Strong-Buy

Terumo (OTCMKTS:TRUMY) was upgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Tuesday, Zacks reports.

Separately, Nomura upgraded shares of Terumo from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 30th. Two analysts have rated the stock with a Strong Buy rating. According to MarketBeat, the company currently has a consensus rating of “Strong Buy”.

Terumo Price Performance

Shares of OTCMKTS:TRUMY opened at $14.15 on Tuesday. The company has a quick ratio of 1.37, a current ratio of 2.19 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $20.87 billion, a PE ratio of 19.93 and a beta of 0.77. The firm’s 50 day moving average price is $15.11 and its 200-day moving average price is $14.22. Terumo has a twelve month low of $12.08 and a twelve month high of $17.81.

Terumo (OTCMKTS:TRUMY) last announced its earnings results on Friday, August 7th. The company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.17 by $0.13. Terumo had a net margin of 13.83% and a return on equity of 10.44%. The company had revenue of $1.97 billion during the quarter, compared to analyst estimates of $1.84 billion. Equities research analysts expect that Terumo will post 0.86 EPS for the current year.

Terumo Company Profile

Terumo Corporation is a Japan-based medical technology company that develops, manufactures and sells products used in hospitals, clinics and other healthcare settings. Founded in 1921 by a group of Japanese medical doctors, the company initially produced clinical thermometers and has since expanded into a global provider of medical devices and related services.

Terumo’s principal businesses include cardiac and vascular products, blood and cell technologies, and general hospital solutions.